78 related articles for article (PubMed ID: 26440638)
1. Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.
Imai C; Harazaki T; Inoue S; Mochizuki K; Goda T
J Nutr Sci Vitaminol (Tokyo); 2015; 61(4):313-21. PubMed ID: 26440638
[TBL] [Abstract][Full Text] [Related]
2. Treatment with the α-glucosidase inhibitor miglitol from the preonset stage in Otsuka Long-Evans Tokushima Fatty rats improves glycemic control and reduces the expression of inflammatory cytokine genes in peripheral leukocytes.
Mochizuki K; Fukaya N; Tanaka Y; Fuchigami M; Goda T
Metabolism; 2011 Nov; 60(11):1560-5. PubMed ID: 21550076
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
Imai C; Harazaki T; Inoue S; Mochizuki K; Goda T
Biosci Biotechnol Biochem; 2013; 77(11):2305-8. PubMed ID: 24200798
[TBL] [Abstract][Full Text] [Related]
4. The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading.
Tanaka Y; Mochizuki K; Fukaya N; Shimada M; Goda T
Br J Nutr; 2009 Jul; 102(2):221-5. PubMed ID: 19138443
[TBL] [Abstract][Full Text] [Related]
5. The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats.
Fukaya N; Mochizuki K; Tanaka Y; Kumazawa T; Jiuxin Z; Fuchigami M; Goda T
Eur J Pharmacol; 2009 Dec; 624(1-3):51-7. PubMed ID: 19818342
[TBL] [Abstract][Full Text] [Related]
6. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
[TBL] [Abstract][Full Text] [Related]
7. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
8. The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes.
Fukaya N; Mochizuki K; Shimada M; Goda T
Nutrition; 2009 Jun; 25(6):657-67. PubMed ID: 19216056
[TBL] [Abstract][Full Text] [Related]
9. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
11. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Kishimoto M; Noda M
Clin Drug Investig; 2015 Feb; 35(2):141-7. PubMed ID: 25511640
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of β2 integrin genes in rat peripheral leukocytes by inhibiting postprandial hyperglycemia.
Mochizuki K; Shimada M; Tanaka Y; Fukaya N; Goda T
Biosci Biotechnol Biochem; 2010; 74(12):2470-4. PubMed ID: 21150098
[TBL] [Abstract][Full Text] [Related]
14. S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy.
Kondo S; Mochizuki K; Hariya N; Saito M; Doguchi S; Osonoi T
Drugs R D; 2021 Mar; 21(1):91-101. PubMed ID: 33464544
[TBL] [Abstract][Full Text] [Related]
15. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Hariya N; Mochizuki K; Inoue S; Saito M; Fuchigami M; Goda T; Osonoi T
Drugs R D; 2014 Sep; 14(3):177-84. PubMed ID: 25079671
[TBL] [Abstract][Full Text] [Related]
16. Effect of Anagliptin on Vascular Injury in the Femoral Artery of Type 2 Diabetic Rats.
Noda M; Kikuchi C; Hori E; Iwao T; Nagami C; Takeuchi M; Matsunaga T
Biol Pharm Bull; 2024; 47(1):204-212. PubMed ID: 38246646
[TBL] [Abstract][Full Text] [Related]
17. Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
Kitano D; Chiku M; Li Y; Okumura Y; Fukamachi D; Takayama T; Hiro T; Saito S; Hirayama A
Cardiovasc Diabetol; 2013 Jun; 12():92. PubMed ID: 23777506
[TBL] [Abstract][Full Text] [Related]
18. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
[TBL] [Abstract][Full Text] [Related]
19. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
20. Antihyperglycemic effect of stem bark powder from paper mulberry (Broussonetia kazinoki Sieb.) in type 2 diabetic Otsuka Long-Evans Tokushima fatty rats.
Cha JY; Kim YT; Kim HS; Cho YS
J Med Food; 2008 Sep; 11(3):499-505. PubMed ID: 18800898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
